Idarubicin Hydrochloride
Brand Names: Idamycin Pfs
Methodology & AI Transparency ⓘ
Idarubicin Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage idamycin pfs: is indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen.
- 2 Real-world patient consensus: 81% patient "Worth It" rating across 17 anonymous logs for Idarubicin Hydrochloride (RxNorm 1791493).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $53.05 cash mean against $129.97 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Idarubicin Hydrochloride tolerability events: nausea (13%), diarrhea (10.3%), abdominal discomfort (5.8%).
Ask our AI Specialists anything about Idarubicin Hydrochloride
Idarubicin Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage idamycin pfs: is indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen. IDAMYCIN PFS is an anthracycline topoisomerase inhibitor indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen. (1)
12.1 Mechanism of Action Idarubicin hydrochloride has antimitotic and cytotoxic activity through forming complexes with the DNA, inhibiting nucleic acid synthesis, inhibiting topoisomerase II activity, and producing DNA-damaging free radicals.
Clinical clearance of Idarubicin Hydrochloride (Anthracycline Topoisomerase Inhibitor) relies on mixed metabolic conjugation and unchanged urinary excretion across idarubicin hydrochloride regimens with a Terminal t½ estimated at 7–20 hrs depending on renal/hepatic reserve (Idarubicin Hydrochloride) half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Idarubicin Hydrochloride (1 mg/mL Injection, Solution) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after idarubicin hydrochloride administration.
FDA clinical labeling for Idarubicin Hydrochloride restricts administration in prior anaphylaxis, angioedema, or severe hypersensitivity to idarubicin hydrochloride or idarubicin hydrochloride excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-04-15 idarubicin hydrochloride spl across 1 mg/mL Injection, Solution, 1 mg/mL Solution, with self-reported patient tracking dominated by nausea (13% of reports), diarrhea (10.3% of reports), headache (8.5% of reports).
Avoid overlapping anthracycline topoisomerase inhibitor prescriptions alongside Idarubicin Hydrochloride to prevent cumulative receptor toxicity.
Unstandardized herbal extracts may interact pharmacodynamically with Idarubicin Hydrochloride maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Idarubicin Hydrochloride or Idarubicin Hydrochloride excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-04-15 Idarubicin Hydrochloride SPL
Logged Side-Effect Incidence (17 Reports)
Idarubicin Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Idarubicin Hydrochloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk Caution should be taken when choosing IDA-BuCy for IR-AML patients in CR1 with auto-HSCT. American journal of hematology • 2023-03-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36588387 ↗ |
| Can This Approach Help? Inside the Latest Research on Consolidation Strategies for children Patients With Acute Myeloid Leukemia: CONS with 2 cycles of chemotherapy was not significantly better than the standard CONS in reducing the cumulative risk of relapse among newly. Journal of pediatric hematology/oncology • 2025-07-01 • Phase III Randomized Trial | N = 52 | 82/100 | PMID 40367210 ↗ |
Idarubicin Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.1000/unit (~$33.00/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $129.97 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $53.05 / mo | View logs ↓ |
Idarubicin Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Idarubicin Hydrochloride RxNorm Concept ID | 1791493 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.1000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $129.97 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $53.05 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 81.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Idarubicin Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Cross-verified Idarubicin Hydrochloride (anthracycline topoisomerase inhibitor) monograph synthesizing RxNorm 1791493, openFDA FAERS signals, and $53.05–$129.97 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Idarubicin Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.